CyFlow CD20 APC-Cy7
品番 | BN667775 | ||
---|---|---|---|
抗体名 | Anti-Hu CD20 APC-CY7,2H7 | ||
包装単位 | 100 tests | ||
濃度 | - | ||
容量 | 0.4 ml | ||
関連製品 (アイソタイプコントロール) |
- | ||
反応性|交差吸着 | Human | Non-Human Primates | レーザー | Red |
抗原 | CD20, B1, Bp35 | 最大蛍光波長 | 780 nm |
クローン | 2H7 | 最大励起波長 | 650 nm, 750 nm |
ホスト | Mouse | 標識/Format | APC-Cy7 |
アイソタイプ | IgG2b | 研究分野 | Immunophenotyping | Signaling |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD20 APC-CY7,2H7
特異性
The mouse monoclonal antibody 2H7 recognizes CD20 antigen, a 33-37 kDa non-glycosylated membrane receptor with four transmembrane domains, expressed on pre-B lymphocytes, resting and activated B cells (not plasma cells), follicular dendritic cells, and at low levels on peripheral blood T lymphocytes.
抗原情報
CD20 (B1, Bp35) is a cell surface 33-37 (depending on the degree of phosphorylation) kDa non-glycosylated surface phosphoprotein expressed on mature and most malignant B cells, but not stem cells or plasma cells (low number of the CD20 has been also detected on a subpopulation of T lymphocytes and it can be expressed on follicular dendritic cells). Its expression on B cells is synchronous with the expression of surface IgM. CD20 regulates transmembrane calcium conductance (probably functioning as a component of store-operated calcium channel), cell cycle progression and B-cell proliferation. It is associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following mAb treatment.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, Glennie MJ, Cragg MS: CD20‑induced lymphoma cell death is independent of both caspases and its redistribution into triton X‑100 insoluble membrane rafts. Cancer·Res. 2003·Sep·1; 63(17):5480‑9. <·PMID:·14500384·>
• Clark EA, Yokochi T: Human B Cell and B cell blast‑associated Surface Molecules defined with Monoclonal Antibodies. in:·Leucocyte·Typing·—·Bernard·A,·et·al.·(Eds). 1984; 339‑346.:339‑346. <·PMID:·Springer·68857-7_23·>
• Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P: Association of 75/80‑kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20: Evidence against involvement of the cytoplasmic regions of CD20. J·Biol·Chem. 1995·Sep·22; 270(38):22632‑8. <·PMID:·7545683·>
• Deans JP, Robbins SM, Polyak MJ, Savage JA: Rapid redistribution of CD20 to a low density detergent‑insoluble membrane compartment. J·Biol·Chem. 1998·Jan·2; 273(1):344‑8. <·PMID:·9417086·>
• Diehl SA, Schmidlin H, Nagasawa M, van Haren SD, Kwakkenbos MJ, Yasuda E, Beaumont T, Scheeren FA, Spits H: STAT3‑mediated up‑regulation of BLIMP1 Is coordinated with BCL6 down‑regulation to control human plasma cell differentiation. J·Immunol. 2008·Apr·1; 180(7):4805‑15. <·PMID:·18354204·>
• Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·>
• Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS, Simon A, Bradley C, Thompson PA, Wahl AF, Ledbetter JA: CD20‑directed small modular immunopharmaceutical, TRU‑015, depletes normal and malignant B cells. Clin·Cancer·Res. 2009·Apr·15; 15(8):2739‑46. <·PMID:·19351771·>
• Polyak MJ, Ayer LM, Szczepek AJ, Deans JP: A cholesterol‑dependent CD20 epitope detected by the FMC7 antibody. Leukemia. 2003·Jul; 17(7):1384‑9. <·PMID:·12835728·>
• Polyak MJ, Deans JP: Alanine‑170 and proline‑172 are critical determinants for extracellular CD20 epitopes: heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood. 2002·May·1; 99(9):3256‑62. <·PMID:·11964291·>
• Rose AL, Smith BE, Maloney DG: Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 2002·Sep·1; 100(5):1765‑73. <·PMID:·12176898·>
• McMichael AJ, Beverley PCL, Cobbold S, et al (Eds): Leucocyte Typing III, White Cell Differentiation Antigens. Oxford·University·Press,·Oxford. 1987; 1‑1050. <·NLM·ID:·8913266·>
• Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford·University·Press,·Oxford. 1989; 1‑1820. <·NLM·ID:·8914679·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN